(firstQuint)C-CAR011 Treatment in Subjects With ALL After HSCT.

 A study evaluating safety and efficacy of CBM.

CD19-targeted chimeric antigen receptor T cells (C-CAR011) treatment in subjects with acute lymphoblastic leukemia(ALL) after hematopoietic stem cell transplantation(HSCT).

 The amount of cells received:1.

0-5.

0*10^6CAR+T cells/kg.

 C-CAR011 Treatment in Subjects With ALL After HSCT@highlight

This is a single-center, prospective clinical study evaluating safety and efficacy of C-CAR011 treatment in subjects with ALL after HSCT